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Abstract: Melatonin is mainly produced in the mammalian pineal gland during the dark phase. Its secretion from the  
pineal gland has been classically associated with circadian and circanual rhythm regulation. However, melatonin   
production is not confined exclusively to the pineal gland, but other tissues including retina, Harderian glands, gut, ovary, 
testes, bone marrow and lens also produce it. Several studies have shown that melatonin reduces chronic and acute   
inflammation. The immunomodulatory properties of melatonin are well known; it acts on the immune system by regulat-
ing cytokine production of immunocompetent cells. Experimental and clinical data showing that melatonin reduces   
adhesion molecules and pro-inflammatory cytokines and modifies serum inflammatory parameters. As a consequence, 
melatonin improves the clinical course of illnesses which have an inflammatory etiology. Moreover, experimental   
evidence supports its actions as a direct and indirect antioxidant, scavenging free radicals, stimulating antioxidant   
enzymes, enhancing the activities of other antioxidants or protecting other antioxidant enzymes from oxidative damage. 
Several encouraging clinical studies suggest that melatonin is a neuroprotective molecule in neurodegenerative disorders 
where brain oxidative damage has been implicated as a common link. In this review, the authors examine the effect  
of melatonin on several neurological diseases with inflammatory components, including dementia, Alzheimer disease, 
Parkinson disease, multiple sclerosis, stroke, and brain ischemia/reperfusion but also in traumatic CNS injuries (traumatic 
brain and spinal cord injury) 
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INTRODUCTION 
  Brain tissue is very vulnerable to free radical damage 
because of its high oxygen utilization (20% of the total oxy-
gen inspired), high concentrations of polyunsaturated fatty 
acids [57] and transition metals such as iron, which is in-
volved in the generation of the hydroxyl radical [76], and 
low concentrations of cytosolic antioxidants [44, 56, 152]. 
Glutathione (GSH) is the predominant antioxidant in the 
brain that is present at millimolar concentrations [174]. 
Melatonin, a secretory product of the pineal gland, is a ubiq-
uitously acting direct free radical scavenger and also an indi-
rect antioxidant [6, 197]. Melatonin, as well as its metabo-
lites, are efficient in detoxifying reactive oxygen species 
(ROS), e.g., HO• and H2O2 [194], and they also interact 
directly with reactive nitrogen species (RNS) [32, 68, 146, 
196]. Endogenous melatonin is synthesized in the pineal 
gland from the neurotransmitter serotonin in a circadian 
manner. In mammals, the melatonin rhythm is generated by 
an endogenous circadian master clock in the suprachiasmatic 
nucleus (SCN) of the hypothalamus, which is entrained by 
the light/dark cycle over a 24-hr period. It participates in 
several neuroendocrine and physiological processes and is 
appropriately referred to as a tissue factor, a paracoid, an 
autocoid, and an anti-oxidant and sometimes as a hormone 
depending on its physiological actions [192]. It has profound 
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anti-oxidant actions against oxidative and nitrosative stress 
[159]. It also exerts significant immunomodulatory influ-
ences [189] and modulates angiogenesis and wound healing 
processes [181]. Melatonin exerts its effects through recep-
tor-mediated and receptor-independent mechanisms, thus, 
manifesting enormous functional versatility and diversity 
[160]. The ubiquitous distribution of melatonin receptors in 
the CNS as well as in the peripheral organs further compli-
ments the fact that melatonin’s actions are not compromised 
by morpho-physiological barriers such as the blood-brain 
barrier. It is likely to influence every cell with which it 
comes into contact. At physiological concentrations, mela-
tonin exerts receptor-mediated actions whereas the receptor-
independent actions usually require higher supraphysiologi-
cal/pharmacological melatonin concentrations because of the 
circumstances under which it is tested. Even at the higher 
concentrations, melatonin is well-tolerated by humans [176]. 
Two melatonin receptors, MT1 and MT2, which belong to 
the G-protein-coupled receptor superfamily, have been 
cloned in mammals and share some specific short amino-
acid sequences, suggesting that they represent a specific sub-
family. A third melatonin-binding site has been purified and 
characterized as the enzyme quinine reductase 2, and the 
inhibition of this enzyme by melatonin may contribute to its 
anti-oxidant properties [138, 195].  
  Exogenous administration of melatonin can also entrain 
the circardian clock by a direct action on SCN and, thus, it 
has potential to treat the disoriented circardian clock in cases 
such as jet-lag, shift-work, in profoundly blind subjects, and 
in individuals with delayed or advanced sleep phase syn-
dromes and sleep inefficiency [72]. Besides being used to Melatonin and Brain  Current Neuropharmacology, 2010, Vol. 8, No. 3    229 
increase sleep efficiency, treat jet lag, improve the cardio-
vascular system [177], and as an antiaging drug [21, 71, 167] 
and a dietary supplement and cancerprotective hormone 
[149], intensive research has indicated melatonin’s beneficial 
effects in experimental models of neurodegenerative disor-
ders. Brain oxidative damage has been implicated as a com-
mon link in the pathogenesis of such diseases.  
MELATONIN AND ITS RECEPTORS 
 Melatonin  (N-acetyl-5-methoxytryptamine) is a natural 
hormone secreted by the pineal gland. In clinical use for 
many years, melatonin is safe and well-tolerated even at high 
doses [214]. Melatonin, or N-acetyl-5-methoxytryptamine, is 
an indole mainly produced in the mammalian pineal gland 
during the dark phase. Melatonin secretion from the pineal 
gland has been classically associated with circadian and cir-
canual rhythm regulation, and with adjustments of physiol-
ogy of animals to seasonal environmental changes [151]. 
Melatonin production, however, is not confined exclusively 
to the pineal gland, but other organs and tissues including 
retina, Harderian glands, gut, ovary, testes, bone marrow and 
lens also have been reported to produce it [128, 193]. In re-
cent years, it has become apparent that melatonin’s actions 
transcended those of a hormonal modulator. Melatonin had 
been shown to subtly influence the function of a variety of 
tissues and cells not generally considered in the endocrine 
category [193]. This led to a suspicion that melatonin had yet 
undefined actions at the cellular level. Numerous data sug-
gest a role for melatonin and its metabolites function in the 
antioxidative defence in all organisms that produce this in-
dole [120, 158, 168, 196], particularly, since melatonin 
crosses all morphophysiological barriers and enters all cells. 
Several mechanisms have been proposed for the neuropro-
tective effect of melatonin. Melatonin upregulates antioxida-
tive defensive systems, including the activities of superoxide 
dismutase and glutathione peroxidase as well as the levels of 
glutathione [202]. Furthermore, melatonin and its metabo-
lites scavenge free radicals [147, 190] and thus terminate the 
initiation and propagation of lipid peroxidation. A recent 
studies show that melatonin binds several metals, including 
iron [107, 108] and this effect may attenuate the Fenton reac-
tion and the generation of the hydroxyl radical.  
  It participates crucially in neurogenesis, immunomodula-
tion [182, 200], improving immune defense [118], regulating 
circadian rhythms and sleep [1], eliminating free radicals 
[146, 155, 156, 196], intervening in lipid metabolism [119, 
173], and also inhibiting cancer growth [61]. Mechanisti-
cally, melatonin functions, by acting through G-protein   
coupled membrane receptors, MT1 and MT2 [61, 119, 173] 
and through nuclear receptors RZR/ROR [142].  
  Melatonin also stimulates a host of antioxidative en-
zymes including SOD, glutathione peroxidase (GPx) and 
glutathione reductase (GRd); these actions further reduce the 
oxidation state of cells [6, 122]. 
  Melatonin inhibits the activity of nitric oxide synthase 
and dopamine release, potentiates the inhibitory effect   
of GABA in the central nervous system, modulates the   
serotonin receptors and potentiates the opioid analgesic.  
  Melatonin possesses an electron-rich aromatic indole ring 
and functions as an electron-donor, thereby reducing and 
repairing electrophilic radicals [124]. Of additional interest 
regarding melatonin, is its reported binding to quinone re-
ductase 2 [217]. This enzyme, which is considered a mela-
tonin receptor, is important in the detoxification of pro-
oxidant quinones. Experimental evidence supports its actions 
as an indirect antioxidant when stimulating antioxidant en-
zymes [161], its ability to enhance the activities of other an-
tioxidants and its protection of antioxidant enzymes from 
oxidative damage [126]. 
  Melatonin has two important functional groups which 
determine its specificity and amphiphilicity: the 5-methoxy 
group and the N-acetyl side chain. Once synthesized, the 
majority of melatonin diffuses directly towards the cerebro-
spinal fluid of the brain's third ventricle, while another frac-
tion is released into the blood stream where it is distributed 
to all tissues [33]. Circulating melatonin is metabolized by P-
450 liver enzymes, which hydroxylate this hormone at the 6-
carbon position to yield 6- hydroxymelatonin. This reaction 
is followed by conjugation with sulfuric or glucuronic acid, 
to produce the principal urinary metabolite, 6-sulfatoxy- 
melatonin. In the last step, conjugated melatonin and minute 
quantities of unmetabolized melatonin are eliminated 
through the kidney. In addition to hepatic metabolism, oxida-
tive pyrrole-ring cleavage appears to be the major metabolic 
pathway in other tissues, including the CNS [163]. Mela-
tonin exhibits high affinity binding to its receptors, of less 
than 500 pM [77]. There are four different melatonin recep-
tor subtypes. Two of them are membrane-associated recep-
tors, while the other two are nuclear receptors. Membrane 
melatonin receptors are classified based upon their kinetic 
properties and pharmacological profiles into MT1 and MT2 
melatonin receptor subtypes [186]. They belong to the seven 
transmembrane receptor family, have 60% aminoacid ho-
mology, and differ in molecular structure and gene chromo-
somal localization [162]. MT1 andMT2 melatonin receptor 
subtypes are present in humans and other mammals [162]. 
The MT2 melatonin receptor has lower affinity (Kd=160 
pmol/l) for 
125I-melatonin as compared to the human MT1 
melatonin receptor (Kd=20-40 pmol/l) [186]. Although sev-
eral authors proposed the existence of a putative MT3 mela-
tonin receptor subtype, recent studies have provided evi-
dence that the MT3 melatonin receptor is actually a cytosolic 
quinine reductase 2 enzyme rather than a membrane receptor 
[117]. For this reason, the MT3 melatonin receptor subtype 
is no longer recognized in IUPHAR's classification as a G 
protein-coupled melatonin receptor subtype. Melatonin is 
also a ligand for retinoid orphan nuclear hormone receptors 
[12], referred to as RZR and RZR at concentrations in the 
low nanomolar range. Both receptors are present in the cen-
tral and peripheral nervous system and have been associated 
with cell differentiation and immune response regulation 
[179]. The RZR melatonin receptor has been implicated in 
inflammatory reactions. Thus, Steinhilber et al. [183] re-
ported that melatonin can down-regulate the expression of 5-
lipooxygenase (5-LOX), an important inflammatory media-
tor, in B lymphocytes via RZR receptors.  
  Several groups have shown that melatonin reverses 
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ment also causes an important reduction of nitric oxide (NO) 
and malondialdehyde (MDA) levels, two compounds that are 
closely related to inflammation [15]. Communication be-
tween the brain and the immune system involves a complex 
network of bidirectional signals which link the neural, endo-
crine, and immune systems [104, 131]. Cerebral disorders 
disrupt the functional interaction between the nervous and 
immune systems [27]. The immunomodulatory properties of 
melatonin are well known; it acts on the immune system by 
regulating cytokine production of immunocompetent cells 
[26, 67]. Experimental and clinical data showing that mela-
tonin reduces adhesion molecules and pro-inflammatory   
cytokines including IL-6, IL-8, and tumor necrosis factor 
(TNF)- and modifies serum inflammatory parameters. As  
a consequence, melatonin improves the clinical course of 
illnesses which have an inflammatory etiology [148].  
  Melatonin has several additional anti-inflammatory ef-
fects, which are probably related to a direct interaction with 
specific binding sites located in lymphocytes and macro-
phages [141] (Fig. 1).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). The regulative pathway of melatonin synthesis in pineal 
gland and the action sites of melatonin in biological system. 
EFFECT OF MELATONIN ON NEURODEGENERA-
TIVE DISORDERS 
  The inherent biochemical and physiological characteris-
tics of the brain, including high polyunsaturated fatty acids 
and energy requirements, make it particularly susceptible to 
free radicals mediated insult [23]. Increasing evidence indi-
cates that accumulation of aberrant or misfolded proteins, 
protofibril formation, ubiquitin proteasome system dysfunc-
tion, excitotoxic insult, oxidative and nitrosative stress, mi-
tochondrial injury and failure of axonal and dendritic trans-
port represent unifying events in many slowly progressive 
neurodegenerative disorders [171].  
  Several effects of melatonin through its receptors may 
account for its ability to prevent oligodendroglial damage: 
free radical scavenger production by activated microglia 
[130, 196], improvement of membrane fluidity and reduction 
of edema and polymorphonuclear cell infiltration into dam-
aged tissue, prevention of translocation of the nuclear factor-
kappa-B (NF-B) to the nucleus and the subsequent reduc-
tion of pro-inflammatory cytokines expression, which play a 
relevant role in the inflammatory reaction [123, 125]. In ad-
dition, melatonin could modulate astrocyte reactivity or 
death through an upregulation of astrocytic anti-oxidative 
defenses [22]. The neuroprotective pathway appears to im-
plicate both melatonin receptors and inflammatory modula-
tion, leading to a promotion of oligodendrocyte maturation. 
  NO plays crucial roles in the brain such as neuromodula-
tion, neurotransmission and synaptic plasticity, but is also 
involved in pathological processes including neurodegenera-
tion and neuroinflammation [62]. It is now well documented 
that NO and its toxic metabolites can inhibit components of 
the mitochondrial respiratory chain leading to cellular energy 
deficiency and, eventually, to cell death [46]. Astroglial cells 
become “activated” in a wide range of CNS pathologies, 
leading to the induction of iNOS [17, 48]. Although glial 
activation can be protective, excess activation causes damage 
in most occasions [133] since the NO formed may inhibit 
neuronal respiration. Formation of NO by astrocytes has 
been suggested to contribute, via impairment of mitochon-
drial function, to the neurodegenerative process. In addition, 
a relationship between neuronal injury and NO originated 
from glial cells has been suggested [41] since activation of 
iNOS results in the release of large amounts of NO neuro-
toxic over long periods of time [121, 222]. Several possibili-
ties have been proposed for neurodegenerative damage in 
CNS, including oxidative stress. Astrocytes are involved in 
multiple brain functions in physiological conditions partici-
pating in neuronal development, synaptic activity and they 
also actively participate in the processes triggered by brain 
injuries, aimed at limiting and repairing brain damage [47]. 
Reactive astrocytes have been implicated in several neuro-
logical diseases with inflammatory components, including 
HIV-1- associated dementia, Alzheimer disease (AD), multi-
ple sclerosis and stroke [69, 129]. Astrocytes contribute to 
the neuroprotection and survival of neurons; any astrocytic 
dysfunction seriously affects neuronal viability. In addition, 
astrocytes preserve neuronal survival through inactivation of 
ROS. Glia become activated by inflammatory mediators and 
express new proteins such as the iNOS [121]. NO produced 
by iNOS seems to be a key mediator of such glial-induced 
neuronal death. 
  In recent decades, neuroinflammation has been proposed 
as a causative factor of neurological diseases and disorders 
[200]. The chronic inflammatory state would create an acti-
vated immune response, including acute phase protein re-
sponse, cytokines (interferons and interleukins), macro-
phages, lymphocytes, and other immune system cells as well 
[191]. Oxidative stress in the brain occurs when the genera-
tion of ROS exceeds the ability of the endogenous antioxi-
dant system to remove excess ROS subsequently leading to 
cellular damage. The presence of oxidative stress in brain 
mitochondria should cause changes in LPO and GSH and, if 
ROS damage is prolonged, also changes should occur in en-
zymes of the redox cycle of GSH [122]. 
  Melatonin, with antioxidant and anti-inflammatory well  
documented actions [32, 83, 146, 165, 166, 190, 197], showed  
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function with age. These effects, and the fact that melatonin  
virtually lacks toxicity even at large doses [42, 84, 114],   
supports its clinical use in preventing the impairments of   
aging. Due to the lipophilicity of melatonin, it is accumulated  
by the mitochondria at high concentrations [36], allowing its  
interaction with mitochondrial membranes [150], possibly   
locating near the polar heads of membrane phospholipids   
[90]. In this location, melatonin may easily protect brain   
mitochondrial membranes from free radical attack, stabiliz- 
ing them [102]. The ability of melatonin to prevent GSH loss  
with age probably reflects its effect on the activities of the  
GSH redox cycle enzymes [122].  
  Mitochondria have been identified as a target for mela-
tonin [5, 92]. Melatonin promotes mitochondrial homeosta-
sis. Melatonin may be possible to treat neurodegenerative 
disorders by inhibiting mitochondrial cell death pathways 
[82, 112, 180, 205]. Studies show that melatonin levels are 
lower in AD patients compared with that in age-matched 
control subjects [112, 116, 140]. The great advance has been 
currently conduced in studies of protection against AD by 
antioxidant melatonin inhibiting A-induced toxicity [52-55, 
85, 100, 225] and attenuating tau hyperphosphorylation [43, 
105, 113, 143, 210, 211, 213]. Besides the antioxidant prop-
erties, the anti-amyloidogenic properties of melatonin for 
AD have been studied [86, 144]. Melatonin improved learn-
ing and memory deficits in an APP695 transgenic mouse 
model of AD in vivo [52]. In vitro experiments showed that 
A-treated cultures exhibited characteristic features of apop-
tosis, and melatonin attenuated A-induced apoptosis in a 
number of cellular models of AD including mouse microglial 
BV2 cells, rat astroglioma C6 cells, and PC12 cells [43, 52, 
54, 145, 225]. Studies in transgenic AD mice and cultured 
cells have suggested that administration of melatonin inhib-
ited the A-induced increase in the levels of mitochondria 
related Bax [43, 55]. Furthermore, melatonin prevented 
upregulated expression of Par-4 and suppressed A-induced 
caspase-3 activity [55]. Another experiment in mouse micro-
glial BV2 cells in vitro showed that melatonin also decreased 
caspase-3 activity, inhibited NF-B activation, and reduced 
the generation of A-induced intracellular ROS (reactive 
oxygen species) [53]. In addition,  in vivo observations 
showed that melatonin-treated animals had diminished ex-
pression of NF-B compared to untreated animals [209]. 
Another experiment demonstrated that melatonin inhibited 
the phosphorylation of nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase via a PI3K/Akt-dependent sig-
naling pathway in microglia exposed to A1-42 [100]. Taken 
together, the above-mentioned evidence suggests that mela-
tonin may provide an effective means of treatment for AD 
through its antiapoptotic activities. 
  Mounting evidence indicates that melatonin blocks the 1-
Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-
dependent apoptotic fragmentation of nuclear DNA in rat 
astrocytes [89], rat mesencephalic cultures [80], and mouse 
striatal neurons [81]. Besides its traditional role as an anti-
oxidant and free radical scavenger, melatonin proved to tar-
get a variety of pathways while its systemic effect correlates 
with the drug’s disruption of the intrinsic mitochondrial cell 
death pathway, silencing of the Rip2/caspase-1 pathway, and 
the activation of survival pathways. These actions may be 
synchronistic and complementary in models of HD. Effec-
tive treatment to prevent neurodegeneration could be 
achieved using a combination of melatonin and other phar-
macological agents that act on different apoptosis targets. 
  Antiinflammatory actions of melatonin depend on its 
inhibition of the expression of iNOS and, here, mitochon-
drial iNOS [38, 49]. It was recently reported that the brain 
melatonin metabolite N1-acetyl-5-methoxykynuramine (AMK) 
[163] is a better antioxidant than its precursor AFMK [164], 
and it is a highly efficient NO scavenger, which forms a sta-
ble product that does not easily re-donate NO [73]. AMK 
was more potent than melatonin in inhibiting in vitro and in 
vivo striatal NOS activity [103], and both compounds, mela-
tonin and AMK, easily cross the brain-blood barrier after 
their administration, reaching neuronal and glial cells [16, 
19, 103]. Moreover, several of the melatonin metabolites, in 
addition to AMK, and including 3-hydroxymelatonin, and 
AFMK are likewise free radical scavengers [146, 196]. With 
regard to the anti-inflammatory effects of melatonin, the 
most important feature is its inhibition of iNOS expression 
[38]. Antioxidant and anti-inflammatory properties of mela-
tonin are relevant in mitochondrial physiology [16], and they 
may play a neuroprotective role in PD. AMK is a potent in-
hibitor of mitochondrial iNOS activity and a more efficient 
NO scavenger than its precursor melatonin [73].  
  Melatonin is known to be a stabilizer or protector of cell 
and organelle membranes because of its inhibitory effects on 
lipid peroxidation [153]. Melatonin has a regulatory effect on 
the activities of enzymes involved in the generation of free 
radicals, and on microsomal membrane fluidity in situations 
of elevated oxidative stress [208]. Moreover, its solubility in 
lipid and aqueous media, which allows it to cross morpho-
physiological barriers and enter subcellular compartments, 
permit melatonin to function as a highly effective inhibitor of 
oxidative damage. Our results indicate that melatonin stabi-
lizes C6 glioma cell line membranes. Thus, melatonin’s abil-
ity to stabilize membranes may contribute to its neuroprotec-
tive actions. Recent work shows that melatonin prevents 
specifically the activation of the pro-inflammatory enzymes 
COX-2 and iNOS in glioma cells without simultaneous   
inhibition of COX-1 enzyme, thus indicating an anti-
inflammatory action. In fact, COX-2 inhibition by melatonin 
may account for many protective effects including those ob-
served in neurodegenerative diseases. Importantly, melatonin 
did not alter COX-1 protein level, one of the major disadvan-
tages of using NSAIDs is their side effect on COX-1 [66]. 
Due to its lack of effect on COX-1, melatonin could poten-
tially share the benefits of NSAIDs while avoiding their side 
effects. Moreover, melatonin lowered the nitrite/nitrate pro-
duction by reducing iNOS expression in LPS/IFN- through 
the inhibition of NF-B activation. Inhibition of NF-B by 
melatonin has been previously reported in other experimental 
models that show how melatonin prevents NF-B activation 
by oxidative stress [24]. Moreover, our study showed an 
inhibitory effect of melatonin on nNOS expression in glioma 
cell line, confirming a role of noncompetitive inhibitors of 
the nNOS. Additional studies are required to define the spe-
cific concentrations of melatonin to inhibit oxidative damage 
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NO-induced impairment and this effect is associated with 
decreased formation of oxidatively modified proteins and 
with decreased upregulation oxidative stress-responsive 
genes, such as Hsp70. Expression of stress responsive genes, 
such Hsp70, used as indicator of astroglial stress, is mark-
edly inhibited, consistent with a protective effect of mela-
tonin.  
EFFECT OF MELATONIN ON TRAUMATIC CNS 
INJURIES 
  Traumatic CNS injuries include traumatic brain injury 
(TBI) and SCI, depending on the anatomical region dam-
aged. It is crucial to relate melatonin’s efficacy to the aber-
rant Ca2+-homeostasis-driven signaling pathways as they 
form a common denominator to any traumatic CNS injury. 
Melatonin is highly effective in preventing molecular mutila-
tion due to aberrant Ca2+-homeostasis. A recent experimen-
tal study in aged mice found that oral administration of mela-
tonin restored the metabolic function of cells with improve-
ment in several aspects of Ca2+-signaling such as the ampli-
tude and frequency, the size of intracellular Ca2+-pools, ca-
pacitative Ca2+-entry, and the mitochondrial potential [102, 
202]. Such aberrant Ca2+-homeostasis during aging is un-
doubtedly a slow and gradual process that causes the accu-
mulation of molecular debris over time. Some benefits of 
melatonin may also be expected when sudden neurotrauma 
disturbs tightly regulated Ca2+-signaling processes. This 
evidence comes from the experimental studies where mela-
tonin alleviated the impaired large conductance of Ca2+-
activated K+ channel activity in hippocampal neurons, which 
were injured as a result of intermittent hypoxia [201] or in 
ischemia-reperfusion injury in chronically hypoxic rats 
[219]. Melatonin receptors, in addition to coupling with the 
heterotrimeric G proteins, also physically associate with 
other intracellular proteins, e.g., calmodulin [141], and such 
interactions multiply the modulatory functions of melatonin 
in cell signaling [87] and cytoskeltal rearrangements [13, 
79]. Moreover, melatonin receptors undergo heterodimeriza-
tion as MT1/MT2, although the functional consequences of 
this association on receptor signaling and trafficking are cur-
rently unknown [87]. The advantages of therapeutic and 
clinical utilization of melatonin have been repeatedly empha-
sized [2, 99] and such encouragement may, in due course, 
lead to an efficient neuroprotective intervention in CNS 
trauma. One may expect dual benefits of melatonin admini-
stration in traumatic CNS injuries. Firstly, it may be impor-
tant to restore the perturbed endogenous melatonin rhythm if 
it is disturbed by mechanical interruption of melatonin syn-
thesis due to damage to the neural connections between the 
SCN and the pineal gland. Secondly, it may be a result of its 
multiple neuroprotective/neurorestorative actions that mela-
tonin has at the site of injury in the CNS. Progression of 
traumatic CNS injuries follow an archetypal course through 
primary and secondary damaging events, which are distinct 
in their spatiotemporal windows. Because of melatonin’s 
multiple actions, its use as a treatment may profoundly influ-
ence both the short-term primary damaging events as well as 
preventing some of the long-term secondary damage. The 
half-life of exogenously administered melatonin in the blood 
is short; hence, there is a need for stable melatonin mimetics, 
be they synthetic ligands or receptor modulators. To date, 
these melatonin analogs have not been tested for their possi-
ble benefits in SCI or any CNS injury. 
  Clinically, SCI involves two components: an initial me-
chanical instability precipitating into a secondary injury 
process leading to the final neurological deficit [109]. Trau-
matic SCI may be a direct lesion that causes focal injury to 
the neural elements at the site of impact or a lesion due to 
stretching or compressive forces applied to spinal cord via 
bones and/or ligaments. In either case, the cord lesion ex-
pands with time following injury over adjoining spinal seg-
ments causing secondary injury. Primary injuries cause dis-
ruption of the blood supply to spinal cord and lead to 
ischemic damage. A quest for a good neuroprotectant in SCI 
remains unresolved. A possible correlation between the neu-
roprotective efficacy of melatonin and SCI originally 
emerged almost three decades ago as clinical case reports in 
which the circardian profiles of endogenous melatonin were 
assessed in SCI patients. Much later the experimental studies 
on the utility of exogenously-applied melatonin in experi-
mental models of SCI were conducted.  
  Levels of melatonin in SCI patients differed strictly with 
respect to the site of injury. SCI disrupting the cervical spinal 
cord significantly perturbed the levels of endogenous mela-
tonin, whereas, an injury at the levels of thoracic or lumbar 
did not affect it severely. These differences are explicable in 
terms of the central neural pathways, which connect the eyes 
to the pineal gland. Lesions within the cervical spinal col-
umn caused decentralization of pineal gland because they 
perturbed descending sympathetic fibers and led to an ab-
sence of significant increment in nocturnal melatonin; this, 
clearly distinguished quadriplegic subjects from normal 
males and from the subject with a lesion of the lumbar spinal 
cord [96]. It was further confirmed that neurologically com-
plete cervical spinal cord transection results in complete loss 
of the circardian melatonin rhythm [223]. More complete 
studies on rhythms of serum melatonin in patients with spi-
nal lesions at the cervical, thoracic, or lumbar region re-
vealed that the cervical region of the spinal cord includes the 
neural pathway, which is essential for the diurnal rhythm of 
pineal melatonin secretion in human. Retrospectively, such 
studies clearly discerned the relationship between regional 
specificity of SCI lesions and changes in the endogenous 
profile of melatonin [106]. Such a regional bias was re-
confirmed in a recent clinical study conducted using tetra-
plegic patients with bilateral oculo-sympathetic paresis 
showing a complete loss of the nocturnal production of mela-
tonin [224]. A recent assessment based on the “Basic Nordic 
Sleep Questionaire" conducted at the Karolinska University 
Hospital in Stockholm, on a large SCI patient population 
comprised of 230 patients, inferred that perturbances in the 
melatonin rhythm contributed to poor subjective sleep qual-
ity associated with higher ratings of pain intensity, anxiety, 
and depression [137]. Another study confirmed the positive 
correlation of an altered melatonin cycle in cervical SCI pa-
tients with reduced sleep quality and documented the need 
for larger studies on the potential usefulness of melatonin 
replacement therapy in normalizing sleep in SCI patients 
[175]. Several encouraging clinical case studies suggest that 
melatonin may be the neuroprotectant of choice in this dev-
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practice to date that is highly useful as a treatment for this 
complex neurological problem. Hence, it is important to as-
sess the outcomes of melatonin’s use in experimental models 
of SCI with the intent of eventually applying this informa-
tion for treatment of SCI in humans. The first experimental 
study to test melatonin’s efficacy in reducing neural damage 
in experimental SCI in animals is that of Fujimoto and col-
leagues [59]. They studied an acute to chronic SCI model 
and showed a significant protection by melatonin against 
neutrophil-mediated damage including lipid peroxidation, 
reduced levels of secondary injury, and an earlier recovery 
[59]. Systemically applied pharmacological doses of mela-
tonin were shown to boost the antioxidant defense system in 
a variety of ways after acute SCI [198]. Melatonin also pro-
tected against autodestruction following SCI by reducing the 
levels of free iron and the products of lipid peroxidation 
[111]. When compared with methylprednisolone, melatonin 
was found to be more effective in an acute SCI model 
against lipid peroxidation and in preserving the structural 
integrity of neurons, axons, and intracellular organelles [91]. 
A later study uncovered the greater efficacy of melatonin 
compared to methylprednisolone in preserving the ultrastruc-
tural histopathological integrity of the spinal cord although 
the reduction of lipid peroxidation after SCI was less obvi-
ous. Furthermore, this study also verified that the neuropro-
tective effect of melatonin was dose-dependent [70]. A com-
bination therapy of melatonin with methylprednisolone did 
show an additive effect against the accumulation of lipid 
peroxidation products in the subacute phase of injury, but did 
not show any difference in a brief chronic 10-day study fol-
lowing SCI in rats as evidenced by neurobehavioral, ultra-
structural, and electrophysiological recovery [29]. However, 
more recently in a SCI model in mice, the combination ther-
apy with melatonin and dexamethasone had a significant and 
important beneficial anti-inflammatory effect by blocking 
the possible progression of secondary injury events after 
SCI. This study showed that the effective dose of dex-
amethasone could be reduced 10-fold when it was given in 
combination with melatonin [63]. In comparison to other 
anti-oxidants such as oxytetracycline or prostaglandin E1, 
melatonin was found to be more potent in ameliorating sec-
ondary damage in an acute model of SCI [203]. Melatonin 
reduces the development of inflammation and tissue injury 
associated with SCI by blocking both oxidative and nitrosa-
tive stress [65]. Moreover, melatonin limits the expression 
and activity of matrix metalloproteinases (MMP-9 and 
MMP-2) thereby also reducing pro-inflammatory TNF- 
expression in a mouse model of traumatic SCI [51]. Moreo-
ver, melatonin’s protective role in SCI was related to the 
regulation of MAPK signaling pathways and the high-
mobility group box 1 protein expression (HMGB1) in mice. 
Melatonin treatment in SCI mice enhanced motor recovery, 
reduced the activation of p38 MAPK, JNK, and ERK1/2, and 
the expression of HMGB1 [50]. An earlier report also 
showed that activation of the endogenous melatonin system 
in the spinal cord reduced the generation, development, and 
maintenance of central sensitization, with a resultant inhibi-
tion of capsaicin-induced secondary mechanical allodynia 
and hyperalgesia [204]. It was recently confirmed in an ex-
perimental model of SCI that exogenously administered 
melatonin reduced mechanical allodynia by altering the ex-
pression of water channel aquaporins [134]. Complementing 
the data regarding the neuroprotective effects in rodent SCI 
models, the beneficial neurobiological effects of melatonin 
have also been demonstrated in the rabbit SCI models. Fur-
ther confirmation of neuroprotective efficacy of melatonin in 
traumatic SCI comes from a study conducted in rabbits 
wherein pinealectomy retarded the recovery rate after SCI, 
and administration of melatonin exogenously to the pinealec-
tomized animals augmented the recovery [7]. The multifunc-
tional efficacy of melatonin treatment after SCI has been 
shown  in vivo by many investigations [172]. Calpain, a 
Ca2+-dependent neutral protease, is known to be a key 
player in the pathogenesis of SCI. Treatment of SCI animals 
with melatonin attenuated calpain expression, inflammation, 
axonal damage, and neuronal death, indicating that mela-
tonin was highly neuroprotective in this situation. Moreover, 
examination of levels of calpain and caspase-3 expression 
and activity indicated significant reductions in the proteolytic 
events in SCI animals after treatment with melatonin.  
  Neutrophils are the first leukocytes to arrive within the 
injured spinal cord [74, 127]. In this setting, neutrophils re-
lease neutral proteases and ROS [39]. In this regard, the pro-
duction of ROS such as superoxide anions, hydrogen perox-
ide, and peroxynitrite, is also associated with local and sys-
temic inflammatory response as well as the neurodegenera-
tive disease [157]. Glucocorticoids (GC) are widely used in 
the management of inflammatory diseases. Glucocorticoids 
exert beneficial effects after acute CNS injury in humans and 
experimental animals [94]. Important data show that GC may 
have a disease-modifying effect in addition to their well-
documented anti-inflammatory actions [18]. In fact, the 
therapeutic management of long-term pathologies with ster-
oids is often linked to a series of unwanted side effects, in-
volving the hypothalamus-pituitary-adrenal axis, the cardio-
vascular system, as well as the fat and bone metabolism [8]. 
Glucocorticoids are among a variety of endogenous com-
pounds that have been suggested to influence melatonin pro-
duction in various vertebrate species, including humans, and 
the existence of the mutual relationship between the pineal 
gland and the hypothalamo-pituitary-adrenal axis has been 
postulated. This study provides the first evidence that the 
combination therapy with melatonin (10 mg/kg) and dex-
amethasone (0.025 mg/kg), used at a dose which are not ef-
fective when administered as single treatment, attenuates: (i) 
the tissue damage, (ii) the infiltration of the spinal cord with 
PMN, (iii) TNF-a expression, (iv) the nitration of tyrosine 
residues, (v) iNOS expression, (vi) apoptosis level, and (vii) 
motor recovery. The anti-inflammatory action observed with 
the combination therapy is also related to the reduction of the 
degree of iNOS protein. In addition, the degree of staining 
for nitrotyrosine was significantly reduced by the treatment 
with the combination therapy in SCI-treated mice. In this 
study, it was shown that the pharmacologic combination of 
melatonin plus dexamethasone reduced the inflammatory 
cell infiltration as assessed by the specific granulocyte en-
zyme MPO. Neutrophils, recruited into the tissue [199], can 
contribute to tissue destruction by the production of reactive 
oxygen metabolites [31, 127], granule enzymes, and cytoki-
nes that further amplify the inflammatory response [206]. 
Already, within 1 hr after SCI, an increased synthesis and/or 
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222]. After SCI, TNF- might serve as an external signal, 
initiating apoptosis in neurons and oligodendrocytes [10, 34]. 
It is well known that Bax, a proapoptotic gene, plays an im-
portant role in developmental cell death [9] and in CNS in-
jury [135]. Similarly, it was shown that the administration of 
Bcl-xL fusion protein (Bcl-xL FP; Bcl-2 is the most ex-
pressed antiapoptotic molecule in adult central nervous sys-
tem) into injured spinal cords significantly increased neu-
ronal survival, suggesting that SCI-induced changes in Bcl-
xL contributed considerably to neuronal death [115]. The co-
treatment of melatonin with dexamethasone in SCI experi-
mental model record features of apoptotic cell death after 
SCI, suggesting that protection from apoptosis may be a pre-
requisite for regenerative approaches to SCI. In particular, 
the co-administration of melatonin with dexamethasone re-
duced Bax expression, while Bcl-2 protein was expressed 
much more in SCI treated mice. This result suggests that 
melatonin with dexamethasone prevents the loss of the anti-
apoptotic way and reduces the pro-apoptotic pathway activa-
tion with a mechanism still to be discovered. Fas (CD95)-
mediated apoptosis is an essential mechanism for the main-
tenance of homeostasis, and the disruption of this death 
pathway contributes to many human diseases [28]. Results 
from our research group, moreover, suggest that co-treatment 
in the acute phase of SCI may decrease the extent of in-
tramedullary spinal cord hemorrhage and damage likely is 
demonstrated by the histologic tissue analysis. Thus, we 
have found in the post-traumatic inflammatory combination 
therapy that melatonin plus dexamethasone exerts a signifi-
cant and important beneficial anti-inflammatory effect by 
blocking the possible progression of secondary damage. Fur-
thermore, our results suggest that in vivo, the combination 
therapy allowed reducting 10-fold the effective dexametha-
sone dose. These findings indicate a novel function of a pos-
sible combination therapy, which provides a key procedure 
for the control of the secondary damage development after 
SCI.  
  SCI is a highly debilitating pathology. Although innova-
tive medical care has improved patient outcome, advances in 
pharmacotherapy for the purpose of limiting neuronal injury 
and promoting regeneration are limited. The complex patho-
physiology of SCI may explain the difficulty in finding a 
suitable therapy [185]. It is known that SCI initiates a series 
of cellular and molecular cascade events [10, 75, 199] and 
that a progressive neuronal injury results from a combination 
of secondary injury factors including ischemia, biochemical 
alterations, apoptosis, excitotoxicity, neurotransmitter accu-
mulation and lipid peroxidation/free radical injury [25]. It is 
believed that inflammatory and immune responses are the 
major component of secondary injury and play a central role 
in regulating the pathogenesis of acute and chronic SCI [3, 
14]. Proteinases and, in particular, matrix metalloproteinases 
(MMPs), are likely mediators of early secondary vascular 
pathogenesis after SCI [136]. MMPs are soluble and cell-
surface bound zinc-dependent endopeptidases that mediate 
cellular infiltration, extracellular matrix degradation and 
release of growth factors and cytokines from the matrix, cell 
migration, tissue damage, remodeling, and repair [20, 132]. 
They are synthesized as inactive precursors, which limits 
their potentially destructive properties, and become activated 
upon removal of the propeptide [184]. The catalytic activities 
of MMPs are highly regulated at multiple levels, including 
transcription, secretion, zymogen activation, and inhibition 
by tissue inhibitors of metalloproteinases (TIMPs) [188]. In 
particular, most MMPs are rapidly upregulated by transcrip-
tion in response to the exposure of a cell to growth factors, 
cytokines, chemokines, extracellular matrix (ECM) compo-
nents and other transcriptional regulators. Transcription is 
followed by translation, and an MMP is first produced in its 
pro-form that requires subsequent conversion to the active 
enzyme. Free radicals, serine proteases and other activated 
MMPs are among the factors that convert a pro-MMP to its 
active enzyme. MMPs activity is required for the inflamma-
tory cell infiltration that occurs following SCI and most 
likely contributes to early barrier disruption. The early in-
flammatory response involves an initial wave of infiltrating 
neutrophils, followed by migration of monocytes and macro-
phages into injured segment. Each of these inflammatory 
cells expresses MMPs, including MMP-2 (gelatinase A), 
MMP-8 (neutrophil collagenase), MMP-9 (gelatinase B), 
MMP-11 (stromelysin-3), and MMP-12 (metalloelastase). 
MMP-2 and -9 degrade types IV and V collagen, and thus 
have the potential to modify constituents of basal laminae 
[101, 178]. Expression of MMP-2 and -9 has been demon-
strated throughout the nervous system during development 
[207] and also in disease states, such as painful nerve injury, 
injured spinal cord, and cerebral ischemia [45]. In the nerv-
ous system, these enzymes are directly involved in axonal 
outgrowth during development [220]. On the other hand, the 
aberrant expression of MMPs is involved in various disease 
processes, e.g., cancer metastasis and CNS disorders includ-
ing multiple sclerosis, stroke, Alzheimer’s disease, and 
trauma [220]. Recently, various studies using experimental 
SCI model have demonstrated an involvement of MMPs in 
the posttraumatic events. In particular, a significant upregu-
lation of MMPs was demonstrated in a mouse SCI compres-
sion model [215]. Moreover, it has been also clearly demon-
strated that the pharmacological blockade of MMPs, limited 
to the first several days after SCI, improves locomotor re-
covery [78]. Recently, it has been pointed out that reactive 
oxygen and nitrogen species regulate MMP activity in vitro, 
and disrupt the balance of MMP activation and inactivation 
[58]. Melatonin exerts protective effects reducing SCI-
induced MMP-9 and MMP-2 activity and expression. 
  Much of the damage that occurs in the spinal cord fol-
lowing traumatic injury is due to the secondary effects of 
glutamate excitotoxicity, Ca2+ overload, and oxidative 
stress, three mechanisms that take part in a spiraling interac-
tive cascade ending in neuronal dysfunction and death [4, 
64]. The role of reactive oxygen-induced damage to spinal 
cord lipids (i.e., lipid peroxidation) and proteins has been 
strongly supported in various studies [217]. Antioxidative 
mechanisms of melatonin as well as its metabolites have 
been suggested to be singlet oxygen quenching and free radi-
cal scavenging during prevention of lipid peroxidation [5, 
139]. Decreasing oxidative stress reduces the amount of sec-
ondary damage due to trauma. The regulation of MMPs 
identifies another mechanism whereby the melatonin mini-
mizes oxidative damage and inflammation involved in SCI. 
In the CNS, MMPs participate in injury and disease states. In 
brain and spinal cord injury, MMPs, including MMP-2 and 
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rupting the blood-brain/spinal cord barrier and promoting 
inflammation [169, 170]. Consistent with other studies, we 
show that MMP-2, like MMP-9, is upregulated during SCI 
[78, 136]. Various combinations of proinflammatory mole-
cules may provide the signal for induction of MMPs, espe-
cially MMP-9 activity. The anti-inflammatory activity of 
melatonin involves a significant downregulation of MMP-9 
activity and a modest depression MMP-2 activity. Therefore, 
the inhibition of the MMP-2, and MMP-9 by melatonin is 
most likely attributed to the suppressive effect on TNF- 
production.  
  The inhibition of mitogen-activated protein kinase family 
members, including extracellular signal-regulated kinases  
(ERK1/2), c-jun N-terminal protein kinases, and p38 kinases, 
is believed to be beneficial in a number of experimental 
models of neurodegenerative diseases, diabetes type II, bipo-
lar disorders, stroke, cancer, sepsis, and chronic inflamma-
tory disease. The protective effect of melatonin might largely 
be accounted for by inhibition of p38 and ERK1/2 MAPK. 
Evidence indicates that ERK1/2 and especially p38 play an 
important role in NO-mediated degeneration of neurons in 
the spinal cord following SCI [218]. Previous studies also 
showed that the expression of activated ERK1/2 and p38 
MAPK in microglia/macrophages may play a key role in 
production of CNS inflammatory cytokines and free radicals, 
such as NO [110]. Inhibition of phosphorylation of p38 
MAPK and to a lesser extent of ERK1/2 reduces iNOS 
mRNA expression and rescues neurons from apoptosis after 
acute traumatic SCI [218]. We also here report that 24 hr 
after SCI, melatonin treatment significantly inhibit HMGB1 
expression. In this study, our research group demonstrate 
that melatonin treatment significantly reduced the SCI-
induced spinal cord tissue alterations as well as improved 
motor function.  
  Like other forms of neurotrauma, TBI involves multifac-
torial etiologies including free radical generation, which 
culminates in oxidative and nitrosative damage, disrupted 
macrocirculation and microcirculation in the vicinity of the 
injury, lymphocytopenia, opportunistic infections, perturbed 
sleep-wake cycles, suppression of nonspecific resistance, and 
toxicity caused by therapeutic agents. Together, these factors 
precipitate into the development of heterogenous clinical 
symptoms in the secondary phase. Melatonin has been ad-
judged as a protective agent against damage following TBI 
in several in vitro and in vivo studies [118]. Enhanced vul-
nerability of brain to such oxidative or nitrosative stress that 
escalates the damage following TBI may be handled more 
deftly by melatonin compared to other antioxidants. Infec-
tion and inflammation complicates TBI in surviving patients. 
Melatonin also aids in inhibition of pro-inflammatory cyto-
kines and activation of adhesion molecules. It would conse-
quently reduce lymphocytopenia and infections by opportun-
istic organisms. Moreover, the chronobiotic capacity of 
melatonin may also reset the natural circadian rhythm of 
sleep and wakefulness, which may serve as a major advan-
tage of melatonin’s use as a therapeutic molecule after trau-
matic injury. It may also reduce the toxicity and enhance the 
efficacy of drugs used in clinical management of TBI such as 
steroidal or nonsteroidal anti-inflammatory agents, anti-ulcer 
agents, anti-psychotics/antidepressants, anti-epileptics and 
also anti-anemic drugs. Similar benefits of melatonin may be 
seen in other traumatic injuries to CNS as well. Finally, 
melatonin, not being restricted by the blood-brain barrier, 
reportedly reduces the contusion volume and stabilizes cellu-
lar membranes preventing vasospasm and apoptosis of endo-
thelial cells that occurs as a result of TBI [118, 156]. 
EFFICACY OF MELATONIN ON BRAIN ISCHE-
MIA/REPERFUSION 
  The integrity of the CNS is highly vulnerable to a transi-
tory interruption of its blood supply; this is specially true of 
the brain which is susceptible to focal or global ischemia. 
Unless ischemia is promptly reversed, reperfusion produces 
further cerebral damage. Ischemia/reperfusion injury is a 
subset of CNS damage that is unfortunately common but 
also occurs with equal frequency in nonneural tissues. In the 
CNS, interruption of the blood supply followed by reperfu-
sion may not always be a result of traumatic assault.  
  Melatonin effectively attenuated ischemic brain injury 
via  the Bcl-2-related survival pathway by increasing the   
expression of Bcl-2 [110] and Bcl-xL [93] in the ischemic 
brain.  
  Several recent reviews [30, 155, 212] summarize the re-
ports that have documented the neuroprotective effects of 
melatonin against ischemia/reperfusion injury to the brain. 
Ischemia (focal or global) causes extensive destruction of 
neural tissue and the primary objective in the clinic is to 
promptly reverse it. Procedures such as acute thrombolysis 
or defibrinogenation, however, are effective only in selective 
patients, and are associated with a significant risk of compli-
cations due to bleeding. To date, a number of neuroprotec-
tants, which were initially found effective in experimental 
studies for stroke therapy, failed in clinical trials. In vivo and 
in vitro evidence in favor of the use of melatonin to protect 
against focal and global cerebral ischemia/reperfusion injury 
has been reviewed [212]. The benefits of conducting further 
experimental studies to examine any synergistic protective 
action by combining melatonin with thrombolysis, defi-
brinogenation or other neuroprotectants are emphasized. The 
planning of phase II and phase III trials in an attempt to de-
fine the potential benefits of melatonin as an acute stroke 
treatment in humans is suggested [212]. When the results of 
all the reports are considered, it is clear that endogenously-
produced and exogenously-administered melatonin reduces 
the degree of tissue damage and limits the behavioral deficits 
associated with experimental models of stroke [155]. The 
most recent updates on melatonin’s efficacy in models of 
stroke come from another review where the potentially wide-
spread applications of melatonin have been showed [30]. 
These studies provide the preclinical tests for melatonin in 
acute stroke therapy, and its application at different treatment 
schedules. Advantageous characteristics of melatonin as a 
neuroprotective drug relates to its bioavailability, its poten-
tial for exerting wide-spread neuroprotective actions, further 
amplified and prolonged by its metabolites [146], its ability 
to reduce inflammation, its capability to protect cytoskeleton 
organization, and its anti-apoptotic actions. Moreover, mela-
tonin does not interfere with the thrombolytic and neuropro-
tective actions of other drugs. An adequate safety profile of 
the drug has been underscored.  236    Current Neuropharmacology, 2010, Vol. 8, No. 3  Esposito and Cuzzocrea 
EFFECT OF MELATONIN ON MIDDLE CEREBRAL 
ARTERY OCCLUSION (MCAO) MOUSE MODEL 
  Melatonin has proved effective not only in the cell-free 
purified mitochondrial system but also inhibits cytochrome c 
release in an middle cerebral artery occlusion (MCAO) 
mouse model [92, 97] and in primary cortical neurons (PCN) 
[97]. Thus, melatonin is likely to interfere with both caspase-
dependent (cytochrome c) and independent (AIF) mitochon-
drial cell death pathways. In vitro and in vivo experiments 
have shown that melatonin prevents the activation of down-
stream caspase-3 in oxygen/glucose deprivation (OGD)-
mediated PCN cell death [97], cerebral ischemia-induced 
mouse injury, and the MCAO rat model [82, 93, 97]. Other 
experiments demonstrate significantly fewer TUNEL-
positive cells [88, 98], reduced levels of cleaved PARP, and 
less DNA fragments [92] are found with administration of 
melatonin in the rat MCAO model. In addition, melatonin 
prevents brain damage, with reduced TUNEL-positive cells 
following transient cerebral artery occlusion (CerAO) [187] 
and transient MCAO model [35], as well as attenuating kai-
nic acid-induced neuronal death, and reduces the number of 
TUNEL-labeled DNA breaks [154]. 
  The neuroprotective role of melatonin is also mediated 
through the enhancement of the PI3-K/Akt survival pathway 
[93, 98] and JNK pathway [93], and restores reduced phos-
phorylated Akt in a model of mouse intraluminal MCAO 
[93]. Melatonin protected neuronal cells from damage by 
enhancing the activation of Akt and its downstream target 
Bad, without affecting the expression of 14-3-3, which acts 
as an antiapoptotic factor through interaction with Bad, thus 
mediating antiapoptosis signals in a rat MCAO model [88]. 
Furthermore, in the same model, melatonin inhibits apoptotic 
signals by preventing the injury-induced decrease of phos-
phorylation of Raf-1, MEK1/2, and ERK1/2 and the down-
stream targets, including Bad and 90-kDa ribosomal S6 
kinase [98]. 
CONCLUSIONS 
  Based on the data summarized herein, the multifunctional 
molecule melatonin may be a useful therapeutic agent for 
treatment of CNS injuries [154] (Table 1). There is a wealth 
of well-documented experimental research to support its use. 
Melatonin is safe, nontoxic, and available in pure form for 
human use as a drug. The results of experimental studies 
provide fundamental information for the effective design and 
Table 1.  Efficacy of Melatonin in Animal Models of Neurodegenerative Disease and CNS Traumatic Injury 
Diseases/Models Effect  References 
Neurodegeneration  •  Inhibits cytochrome c release from mitochondria 
•  Reduces number of DNA breaks 
[141, 142] 
MCAO  •  Decreases cytochrome c release 
•  Attenuates cerebral ischemic injury 
•  Prevents caspase-3 activation 
•  Displays decreased DNA 
•  Decreases TUNEL-positive cells 
[221-223] 
[225] 
Parkinson disease (PD)  •  Prevents cytochrome c release 
•  Prevents m depolarization in astrocytes 
•  Prevents ROS formation 
•  Blocks caspase-3 activation 
•  Prevents DNA fragmentation 
•  Inhibits cell death in SK-N-SH cells 
[128-130] 
Huntington disease (HD)  Neuroprotective   
Amyotrophic lateral sclerosis (ALS)  Reduces ROS   
Alzheimer disease (AD)  •  Reducts Par-4 upregulation 
•  Blocks A25-35-induced apoptosis 
•  Anti-inflammatory effect on A vaccination in mice 
•  Improves spatial memory performance 
•  Protects the wortmannin-induced tau hyperphosphorylation 
[110-124] 
Brain ischemia/reperfusion  •  increases the expression of Bcl-2 and Bcl-xL in the ischemic brain  [217-219] 
Spinal cord injury (SCI)    [158, 161, 164, 167,  
168, 207, 208] 
Traumatic brain injury (TBI)    [42, 45] Melatonin and Brain  Current Neuropharmacology, 2010, Vol. 8, No. 3    237 
execution of clinical trials using melatonin as a neuroprotec-
tive treatment for traumatic CNS injuries. 
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